Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.28 EUR | +0.86% | +1.21% | +4.31% |
May. 28 | FMC briefly burdened by research success in the fight against diabetes | DP |
May. 24 | FMC, Fresenius and Davita rise after Ozempic news | DP |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- With a P/E ratio at 11.84 for the current year and 9.38 for next year, earnings multiples are highly attractive compared with competitors.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.31% | 17.88B | A- | ||
+25.52% | 88.99B | C+ | ||
-24.52% | 74.82B | B- | ||
-5.56% | 25.03B | C+ | ||
-14.25% | 16.43B | B | ||
+2.97% | 15.77B | A- | ||
+79.20% | 13.21B | C+ | ||
+70.11% | 13.09B | C- | ||
+40.44% | 12.9B | B- | ||
+24.51% | 12.7B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FRE Stock
- Ratings Fresenius SE & Co. KGaA